BTZ has been approved for the treatment of multiple myeloma and mantle cell lymphoma.25,27 Despite its success in treating hematological malignancies, BTZ did not received satisfactory therapeutic effect on solid tumors.25,27 Therefore, optimization of combination regimens may help to overcome the resistance of BTZ monotreatment in solid tumors. The gene discussed is CASC3; the disease is hematologic disorder.